hotspot -WSS

hotspot

author：focus 2025-09-14 21:39:29 - browse：8825

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： FDA has safety concerns on CRISPR

WSS

Senate panel to vote on hospitals, PBMs, prisoner care

New lawsuit accuses health insurer Cigna of denying claims in bulk

CDC recommends rationing of RSV shot due to shortages

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

A new crop of companies is reshaping the health data economy

Biden's order seeks to regulate AI risk without stifling innovation

hotspot

hotspot

focus

Sports medicine is finally prioritizing gender equality

What to watch for from Zogenix and Amicus clinical trials

Medical leaders decry Supreme Court decision on affirmative action

The pink breast cancer awareness ribbon needs a redesign

At least 13 dead in Texas as scorching temps continue

Device maker Teleflex to acquire urology company for $600M

Guidelines to prevent youth baseball injuries need more muscle

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Supreme Court strikes down use of affirmative action

The pink breast cancer awareness ribbon needs a redesign

knowledge

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Why patients can’t get everything they want on drug pricing

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Senate panel puts off hardest PBM reforms for another day

Physician subsidies by hospitals soar in wake of No Surprises Act

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Wikipedia

knowledge

explore

explore